Evotec’s May Test: Can a Cash Infusion and New Leadership Reverse the Slide?

Evotec faces pivotal weeks as Q1 results, a shareholder meeting, and a $100M Tubulis deal test its turnaround story amid a sharp analyst split.

The next few weeks will determine whether Evotec’s turnaround story has legs — or if the recent rally was merely a dead-cat bounce. With first-quarter results due in early May and a shareholder meeting in June, the German drug discovery group faces a gauntlet of milestones that could either cement investor confidence or trigger a fresh sell-off.

The stock closed Friday at €5.35, down roughly 5% on the week. That retreat follows a sharp 30% surge over the prior month from a multi-year low of €4.14 in March. Yet the shares remain firmly below the 200-day moving average of €5.83 — a level widely viewed as the gateway to a sustained recovery. Year-to-date, Evotec is still nursing a loss of about 3.5%, while the 12-month decline stands at more than 27%.

A Deal to Bridge the Gap

The most tangible catalyst for the current quarter is the Tubulis transaction. Evotec expects to receive around $100 million upfront from the sale of its stake in Tubulis to Gilead Sciences, plus up to $58 million in potential milestone payments. The closing is scheduled for the second quarter of 2026, providing a welcome liquidity buffer in a year when operating profits remain elusive.

That cash injection comes as the company pushes ahead with its “Horizon” restructuring programme. Evotec plans to shrink its network to ten sites and cut up to 800 jobs, targeting annual cost savings of roughly €75 million by the end of 2027. The restructuring itself will cost about €100 million in cash over three years. Management has explicitly labelled 2026 a transition year, with operational improvements not expected until the second half.

For the full year, Evotec forecasts revenue between €700 million and €780 million, while adjusted EBITDA could slide to between zero and €40 million — a sharp drop from prior levels.

Analyst Opinions Diverge Sharply

The wide dispersion in analyst targets underscores the uncertainty surrounding the stock. RBC Capital Markets maintains an “Outperform” rating with a price target of €10, arguing that hidden value remains unrecognised. Deutsche Bank takes the opposite view, setting a target of €4.50 — below the current share price. H.C. Wainwright recently initiated coverage with a Buy rating and a $7 target, citing a compelling valuation after the prolonged sell-off.

Such a stark split is rare and reflects genuine disagreement over whether the restructuring will deliver or disappoint.

Key Dates on the Horizon

Three events will shape the narrative over the coming weeks:

• 1 May 2026: Ingrid Müller starts as chief operating officer, taking direct control of the Horizon programme’s execution.
• 6 May 2026: First-quarter results are published — the first hard evidence of whether the transition year is on track.
• 11 June 2026: The annual general meeting in Hamburg, where shareholders will vote on Dieter Weinand as the new chairman of the supervisory board.

Weinand, a former Bayer board member who previously led regional operations at Pfizer, Bristol Myers Squibb and Sanofi, brings deep commercial and partnership experience. His appointment signals a strategic emphasis on monetising Evotec’s platform through alliances rather than pure research.

The Real Test

The Q1 numbers on 6 May are the most critical near-term event. If Evotec delivers convincing signals, the stock could make another run at the €6 resistance level. If the figures disappoint, a retreat toward the support zone around €4.80 becomes a real risk.

The second half of 2026 will be the true proving ground. By then, the Horizon programme must begin showing up in the financials, and the Gilead payment needs to arrive as promised. The May quarterly report will provide the first checkpoint on whether Evotec is keeping to that timetable — or falling behind.